Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare

Arthritis & Rheumatology
Huifeng YunJeffrey R Curtis

Abstract

The risks of hospitalized infection associated with biologic agents used to treat rheumatoid arthritis (RA) are unclear. The aim of this study was to determine whether the associated risk of hospitalized infections differed between specific biologic agents used to treat RA. In a retrospective cohort study using Medicare data from 2006-2011 for all enrolled patients with RA, new episodes of treatment with etanercept, adalimumab, certolizumab, golimumab, infliximab, abatacept, rituximab, and tocilizumab were identified. Patients were required to have received another biologic agent previously and to have been continuously enrolled in Medicare medical and pharmacy plans during the baseline period and throughout followup. Followup started on the date of initiation of treatment with the new biologic agent (after previous treatment with a different biologic agent) and ended on the date of the earliest hospitalized infection, at 12 months, after an exposure gap of >30 days, or at the time of death or loss of Medicare coverage. Cox regression analysis was used to calculate the adjusted hazard ratio (HR) for hospitalized infection, adjusting for an infection risk score and other confounders. Of 31,801 new biologic treatment episodes in ...Continue Reading

References

Oct 2, 2002·Arthritis and Rheumatism·Michele F DoranSherine E Gabriel
Mar 6, 2004·Lancet·Lars KlareskogUNKNOWN TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators
Apr 13, 2004·Arthritis and Rheumatism·R N MainiUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Nov 6, 2004·Arthritis and Rheumatism·E William St ClairUNKNOWN Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Grou
Oct 29, 2005·Arthritis and Rheumatism·Joachim ListingAngela Zink
Feb 9, 2006·Annals of the Rheumatic Diseases·P L C M van RielUNKNOWN Add Enbrel or Replace Methotrexate Study Investigators
Jan 2, 2009·Seminars in Arthritis and Rheumatism·Daniel E Furst
Nov 4, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jasvinder A SinghPeter Tugwell
May 19, 2011·Annals of the Rheumatic Diseases·Jeffrey R CurtisElizabeth Delzell
Jun 28, 2011·Clinical Therapeutics·Jeffrey R Curtis, Jasvinder A Singh
Nov 8, 2011·JAMA : the Journal of the American Medical Association·Carlos G GrijalvaJeffrey R Curtis
May 11, 2012·Pharmacoepidemiology and Drug Safety·Robert J GlynnSebastian Schneeweiss
Jun 20, 2012·International Journal of Rheumatic Diseases·Ahmed M DewedarAhmed Fathy
Dec 19, 2012·Rheumatology·Eric M Ruderman

❮ Previous
Next ❯

Citations

Jun 2, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Cong Tri TranFrançoise Lunel-Fabiani
Nov 10, 2012·Rheumatic Diseases Clinics of North America·Kevin L Winthrop
Mar 23, 2017·Expert Review of Clinical Pharmacology·Monika Østensen
Nov 25, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Julie DouthwaiteLutz Jermutus
Sep 20, 2017·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Jawad BilalMuhammad Asim Khan
Mar 2, 2018·Modern Rheumatology·Katsuhiko TakabayashiTakahiro Suzuki
Jul 13, 2019·Pharmacoepidemiology and Drug Safety·Rishi J DesaiUNKNOWN Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Switching Workgroup
May 23, 2019·Multidisciplinary Respiratory Medicine·Nicola CiancioGianluca Sambataro
Nov 2, 2019·Annals of the Rheumatic Diseases·Xintong LiG Caleb Alexander
Mar 29, 2019·Current Opinion in Rheumatology·Michael D George, Joshua F Baker
Jan 5, 2017·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Tsuyoshi Takeda
Apr 1, 2020·Journal of Managed Care & Specialty Pharmacy·Jie ZhangKevin Haynes
Nov 3, 2016·The Journal of Rheumatology·Atsuko MurotaTsutomu Takeuchi
Oct 9, 2018·Arthritis Care & Research·Kevin L WinthropDaniel E Furst
Feb 12, 2019·Arthritis Care & Research·Michael D GeorgeJeffrey R Curtis
Oct 18, 2018·Therapeutic Advances in Musculoskeletal Disease·Graeme Jones, Elena Panova
Jan 20, 2019·Pediatric Rheumatology Online Journal·Arnold NagyBernadett Mosdósi
Dec 20, 2019·Expert Review of Clinical Immunology·Ying-Ming Chiu, Der-Yuan Chen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.